Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
01 February 2001Website:
http://www.exactsciences.comNext earnings report:
01 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 23:42:17 GMTDividend
Analysts recommendations
Institutional Ownership
EXAS Latest News
The personalized medicine market is experiencing significant growth, driven by advancements in genomic technologies and a shift towards more individualized healthcare. In 2024, the market is expected to continue expanding, with projections indicating it could reach approximately $390.65 billion, growing at a compound annual growth rate (CAGR) of around 8.20% from 2024 to 2030.
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.
Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts highlighting the breadth and depth of the company's screening and diagnostic portfolio at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, Ill. Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® t.
The ARK Innovation ETF (NYSEARCA: ARKK) has gained attention recently, and there are three Cathie Wood stocks with strong buy ratings for investors to consider in May. A notable feature of the ARK Innovation ETF is its focused portfolio, usually consisting of 35 to 55 stocks.
Exact Sciences (EXAS) ended the most recent trading session at $63.24, showing a decrease of 0.46% compared to the day before.
Exact Sciences (EXAS) ended the most recent trading day at $63.22, showing a decrease of 1% from the previous day's closing price.
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company's multi-biomarker class approach across a broad range of cancer types, including the m.
Full disclosure, I'm not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks.
What type of business is Exact Sciences?
Exact Sciences Corporation is one of the leading companies in the development of tests for the diagnosis of oncological diseases. It is the developer of several of the most effective test brands in the field of cancer screening and diagnosis - including Cologuard (diagnosis of colorectal cancer) and Oncotype DX (diagnosis of breast, prostate, and colon cancer). Currently, they are working on creating additional tests for other types of cancer. The company was founded in 1995. The headquarters are located in Madison, Wisconsin. Exact has agreements for cooperation and licensing with the Mayo Clinic Foundation for Medical Education and Research, licensing agreements with Hologic, Biocartis, Epic Sciences, and others.
What sector is Exact Sciences in?
Exact Sciences is in the Healthcare sector
What industry is Exact Sciences in?
Exact Sciences is in the Diagnostics & Research industry
What country is Exact Sciences from?
Exact Sciences is headquartered in United States
When did Exact Sciences go public?
Exact Sciences initial public offering (IPO) was on 01 February 2001
What is Exact Sciences website?
https://www.exactsciences.com
Is Exact Sciences in the S&P 500?
No, Exact Sciences is not included in the S&P 500 index
Is Exact Sciences in the NASDAQ 100?
No, Exact Sciences is not included in the NASDAQ 100 index
Is Exact Sciences in the Dow Jones?
No, Exact Sciences is not included in the Dow Jones index
When does Exact Sciences report earnings?
The next expected earnings date for Exact Sciences is 01 August 2024